Summary

Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) is a synthetic analogue of the posterior pituitary hormone vasopressin (antidiuretic hormone, ADH). It retains the antidiuretic activity of vasopressin with markedly reduced pressor effects, making it a research subject of interest for fluid homeostasis, platelet aggregation, and haemostasis studies. It is a licensed prescription-only medicine in the UK.

Overview

Desmopressin is a synthetic nonapeptide that mimics the action of naturally occurring arginine vasopressin (AVP). By substituting 8-D-arginine for 8-L-arginine and deaminating the N-terminal cysteine (position 1), researchers created an analogue with ~2,000–3,000 times greater selectivity for V2 vasopressin receptors over V1a receptors. This translates into potent antidiuretic activity with minimal vasopressor effects.

The compound was first synthesised in the 1960s and has since become one of the most extensively studied peptide therapeutics, with over 1,100 publications indexed on PubMed. In the UK, desmopressin is a licensed prescription-only medicine (POM) available in oral, sublingual, and intranasal formulations under brand names such as DesmoMelt® and Desmospray®.

For research and educational purposes only. Not for human consumption. Desmopressin is a licensed POM in the UK.

Mechanism of Action

Desmopressin acts primarily at V2 vasopressin receptors in the renal collecting duct. Binding to V2 receptors activates adenylate cyclase via Gs proteins, increasing intracellular cyclic AMP (cAMP). This triggers the insertion of aquaporin-2 (AQP2) water channels into the apical membrane of principal cells, dramatically increasing water reabsorption from tubular filtrate. The result is urine concentration and reduction in urine output.

Additionally, desmopressin activates V2 receptors on endothelial cells, stimulating the release of von Willebrand factor (vWF) and factor VIII from Weibel-Palade bodies. This haemostatic action underpins its research interest in bleeding disorders. The mechanism involves cAMP-mediated exocytosis of stored vWF and factor VIII, effectively augmenting primary haemostasis and the intrinsic coagulation pathway.

Research Summary

Evidence Grade: Strong

Desmopressin has robust clinical evidence supporting its use in several domains:

Diabetes Insipidus: Central (cranial) diabetes insipidus is the primary licensed indication. Multiple randomised trials and decades of clinical experience confirm efficacy in reducing polyuria and polydipsia in patients with deficient AVP secretion.

Haemostasis: Desmopressin is used in mild haemophilia A and type 1 von Willebrand disease (vWD). A landmark meta-analysis by Mannucci (1997) and subsequent Cochrane reviews confirm that desmopressin increases factor VIII and vWF levels 2–5 fold in responsive patients, reducing bleeding time.

Nocturia: The pivotal phase 3 trial published by van Kerrebroeck et al. (2010) demonstrated that low-dose desmopressin sublingually significantly reduced nocturnal voids in adults with nocturia.

Research applications: Ongoing research explores desmopressin's potential in platelet dysfunction studies, surgical blood loss reduction, and as a cognitive probe in vasopressinergic neurotransmission research.

Key Studies

  1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders. Blood. 1997;90(6):2131-2139.
  2. van Kerrebroeck P et al. Desmopressin orally disintegrating tablet for nocturia. BJU Int. 2010;106(9):1356-1362.
  3. Franchini M, Mannucci PM. Desmopressin for the treatment of haemophilia. Haemophilia. 2018;24(3):351-355.

Commonly Discussed Protocols

All information is for research and educational purposes only. Desmopressin is a licensed POM — no protocols for unsupervised use are provided.

In published clinical literature, desmopressin has been studied via multiple routes:

  • Intranasal: 10–40 micrograms, with bioavailability of approximately 3–4%
  • Sublingual (oral lyophilisate): 60–240 micrograms, bioavailability approximately 0.1–0.25%
  • Intravenous: 0.3 micrograms per kg body weight (haemostatic dosing)

Fluid intake restriction is critical in any desmopressin protocol to prevent hyponatraemia — a potentially life-threatening adverse effect documented extensively in the literature.

Stacking

No established research protocols combine desmopressin with other peptides. The compound's mechanism (renal water reabsorption and coagulation factor release) is distinct from most research peptides. Theoretical combinations with other haemostatic agents are discussed in the clinical literature but are outside the scope of research-peptide use.

Storage & Reconstitution

  • Storage: Store lyophilised desmopressin at –20°C in the dark. Reconstituted solutions should be stored at 2–8°C and used within 24 hours.
  • Reconstitution: Dissolve in sterile bacteriostatic water for injection. Desmopressin is stable in aqueous solution at physiological pH.
  • Note: Commercial formulations (nasal spray, sublingual tablets) have specific stability profiles — refer to the manufacturer's product information.

Blood Work

If desmopressin is being studied, the following monitoring is documented in clinical literature:

  • Serum sodium: Must be monitored before and within 7 days of initiation — hyponatraemia is the primary safety concern
  • Plasma osmolality and urine osmolality: To assess antidiuretic response
  • Factor VIII and vWF activity: In haemostatic research contexts
  • Urine output and specific gravity: To document antidiuretic effect

Hyponatraemia risk is highest in elderly patients and those with high fluid intake — a key research and safety consideration.

UK Legal Status

Desmopressin is a licensed prescription-only medicine (POM) in the UK. It is regulated by the MHRA and is available on prescription for diabetes insipidus, nocturia, and certain bleeding disorders. It is not a controlled substance under the Misuse of Drugs Act.

Research-grade desmopressin for in vitro or laboratory research may be available from chemical suppliers, but any use in humans without a prescription is illegal. The MHRA has issued guidance on the distinction between research chemicals and licensed medicines — see the UK Legality Guide for Research Peptides.

Vetted UK Vendors

As desmopressin is a licensed POM, it is not sold as a research peptide by the vetted vendors listed on Peptide Data. Researchers requiring desmopressin for legitimate laboratory research should source it through established chemical supply houses with appropriate purity documentation (e.g., HPLC-verified).

References

  1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(6):2131-2139. PMID: 9310533.
  2. van Kerrebroeck P, Reu P, de Groat A, et al. Desmopressin orally disintegrating tablet for the treatment of nocturia: a randomised, double-blind, placebo-controlled trial. BJU International. 2010;106(9):1356-1362. doi: 10.1111/j.1464-410X.2010.09348.x.
  3. Franchini M, Mannucci PM. Desmopressin for the treatment of haemophilia. Haemophilia. 2018;24(3):351-355. doi: 10.1111/hae.13462.
  4. Robertson GL. Desmopressin in the treatment of central diabetes insipidus. Journal of Pediatric Endocrinology and Metabolism. 2002;15(Suppl 4):1351-1356.
  5. Bichet DG. Vasopressin and the regulation of thirst. Annals of Nutrition and Metabolism. 2018;72(Suppl 2):3-7. doi: 10.1159/000488233.

References

  1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(6):2131-2139. PMID: 9310533.
  2. van Kerrebroeck P, et al. Desmopressin orally disintegrating tablet for nocturia. BJU Int. 2010;106(9):1356-1362. doi:10.1111/j.1464-410X.2010.09348.x.
  3. Franchini M, Mannucci PM. Desmopressin for the treatment of haemophilia. Haemophilia. 2018;24(3):351-355. doi:10.1111/hae.13462.
  4. Robertson GL. Desmopressin in the treatment of central diabetes insipidus. J Pediatr Endocrinol Metab. 2002;15(Suppl 4):1351-1356.
  5. Bichet DG. Vasopressin and the regulation of thirst. Ann Nutr Metab. 2018;72(Suppl 2):3-7. doi:10.1159/000488233.